Future Directions in Bronchiectasis Research

Bronchiectasis treatment is challenging, and many recent randomized controlled trials have failed to prove any clinical improvement. The most reasonable explanation for that problem is the high heterogeneity of patients' groups. For that reason, there is an urgent need to find new biomarkers to better stratify patients. The present chapter addresses the future directions in biomarkers, omics technologies, endotypes, and new treatments toward a personalized medicine in the field of bronchiectasis.